Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
"A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety ofAbatacept SC in Combination with Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults with Early Rheumatoid Arthritis who are Methotrexate Naive"	Bristol-Myers Squibb	Terminated	Abatacept	3b	IM101550	King Fahad Medical City (Riyadh)
An Open-label, Baseline-controlled, Multicenter, Phase 3 Dose-titration Study Followed by a Fixed-dose Observation Period to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Children and Adolescents from 5 to less than 18 Years of Age with Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)	Astellas	Rejected	Mirabegron	3	178-CL-206A	N\A
"randomised, multicentre, double-blind, placebo-controlledstudy of ambrisentan in subjects with inoperable chronicthromboembolic pulmonary hypertension (CTEPH)"	GSK	Terminated	Ambrisentan 5 mg	3	AMB115811	N\A
Prospective, Randomized, open label Controlled trial to evaluate the safety and efficacy of Dexmedetomidine Compared with Midazolam in children admitted to Pediatric Critical Care unit (PICU) at KAMC-NGHA (PROMISE)	KAIMRC	Rejected	Dexmedetomidine	3	RC11/084	N\A
A randomized, double blind, placebo controlled, parallel group, pilot study of 1:1 and 20:1 ratio of formulated GWP42003: GWP42004 plus GWP42003 and GWP42004 alone in the treatment of dyslipedemia in subjects with Type 2 diabetes.	GW	Rejected	Cannabidiol & Tetrahydrocannabivarin	2a	GWZMD1190	N\A
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome	Takeda	Rejected	Alogliptin	3	SYR-322_402	N\A
"A RANDOMIZED, PARTIALLY-BLIND, PLACEBO-CONTROLLED, PILOT, DOSE-RANGING STUDY TO ASSESS THE EFFECT OF GWP42003 ON LIVER FAT LEVELS IN SUBJECT WITH FATTY LIVER DISEASE"	GW	Rejected	Cannabidiol	2a	GWZMD1188	N/A
A three-arm, randomized, open-label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenupausal women with estrogen receptor postive, locally advanced, recurrent or metastatic breast cancer after recurrence or progression on prior letrozole or anastrozole.	Novartis	Rejected	Everolimus + Exemestane\Everolimus\Capecitabine	2	CRAD001Y2201	N\A
A phase IIIb, open, multi-country, controlled, randomized study to demonstrate the immunogenicity and safety of GSK Biological meningococcal conjugate vaccine, MenACWYTT (GSK134612) in healthy infants, given on a 3+1 primary and booster (2, 4, 6 and 15-18 months of age), a 1+1 primary and booster (6 and 15-18 months of age), or as a single dose at 15-18 months of age	GSK	Rejected	Infanrix-IPV/HiberixTM/SynflorixTM/GSK 134612	3b	114858	N\A
"Tranexamic acid for the treatment of significant traumatic brain injury:an international randomised, double blind placebo controlled trial"	London School of Hygiene & Tropical Medicine (LSHTM)	Ongoing	(Cyklokapron) Tranexamic Acid	3	ISRCTN15088122	King Saud Medical City (Riyadh)